Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Gains from Investment Securities: 2021-2025

Historic Gains from Investment Securities for Krystal Biotech (KRYS) over the last 4 years, with Sep 2025 value amounting to $18,000.

  • Krystal Biotech's Gains from Investment Securities fell 99.21% to $18,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $14.8 million, marking a year-over-year increase of 132.77%. This contributed to the annual value of $6.1 million for FY2024, which is 19.19% up from last year.
  • Latest data reveals that Krystal Biotech reported Gains from Investment Securities of $18,000 as of Q3 2025, which was down 99.85% from $12.1 million recorded in Q2 2025.
  • Krystal Biotech's 5-year Gains from Investment Securities high stood at $12.1 million for Q2 2025, and its period low was $18,000 during Q3 2025.
  • Its 3-year average for Gains from Investment Securities is $2.3 million, with a median of $1.5 million in 2023.
  • As far as peak fluctuations go, Krystal Biotech's Gains from Investment Securities surged by 823.46% in 2023, and later slumped by 99.21% in 2025.
  • Krystal Biotech's Gains from Investment Securities (Quarterly) stood at $336,000 in 2021, then slumped by 51.79% to $162,000 in 2022, then skyrocketed by 823.46% to $1.2 million in 2023, then declined by 23.80% to $919,000 in 2024, then tumbled by 99.21% to $18,000 in 2025.
  • Its Gains from Investment Securities stands at $18,000 for Q3 2025, versus $12.1 million for Q2 2025 and $1.8 million for Q1 2025.